Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques-Eric Gottenberg

Showing results (1-10 of 311) with videos related to

Pageof 32
Sort By:
Annals of the Rheumatic Diseases|January 28, 2021
Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang <i>et al</i>Renaud Felten, Jacques-Eric Gottenberg
Current Pharmaceutical Biotechnology|January 3, 2012
Primary Sjögren's syndrome: time for prospective cohortsJacques-Eric Gottenberg, Xavier Mariette
Annals of the Rheumatic Diseases|April 3, 2021
Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff <i>et al</i>Renaud Felten, Jacques-Eric Gottenberg
Joint Bone Spine|May 2, 2026
Prescription of Targeted Therapies in patient with a history of cancerEden Sebbag, Jacques-Eric Gottenberg
Methods in Molecular Biology (Clifton, N.J.)|April 8, 2014
Characterization of microRNAs and their targetsGhada Alsaleh, Jacques-Eric Gottenberg
Biochimie|June 15, 2007
Dendritic cells and interferon-mediated autoimmunityJacques-Eric Gottenberg, Gilles Chiocchia
Current Opinion in Rheumatology|July 31, 2010
Pathogenesis of Sjögren's syndrome and therapeutic consequencesXavier Mariette, Jacques-Eric Gottenberg
The Lancet. Rheumatology|January 26, 2024
Advances in treatments for Sjögren's syndrome: the glass is half fullRenaud Felten, Jacques Eric Gottenberg
Joint Bone Spine|June 24, 2008
Rituximab: a new therapeutic alternative in rheumatoid arthritisJean Sibilia, Jacques-Eric Gottenberg, Xavier Mariette
La Revue Du Praticien|March 14, 2012
[Diagnostic criteria for Sjögren's syndrome]Coralie Varoquier, Jean Sibilia, Jacques-Eric Gottenberg
Pageof 32

Showing results (1-10 of 311) with videos related to

Sort By:
Pageof 32
Annals of the Rheumatic Diseases|January 28, 2021
Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang <i>et al</i>Renaud Felten, Jacques-Eric Gottenberg
Current Pharmaceutical Biotechnology|January 3, 2012
Primary Sjögren's syndrome: time for prospective cohortsJacques-Eric Gottenberg, Xavier Mariette
Annals of the Rheumatic Diseases|April 3, 2021
Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff <i>et al</i>Renaud Felten, Jacques-Eric Gottenberg
Joint Bone Spine|May 2, 2026
Prescription of Targeted Therapies in patient with a history of cancerEden Sebbag, Jacques-Eric Gottenberg
Methods in Molecular Biology (Clifton, N.J.)|April 8, 2014
Characterization of microRNAs and their targetsGhada Alsaleh, Jacques-Eric Gottenberg
Biochimie|June 15, 2007
Dendritic cells and interferon-mediated autoimmunityJacques-Eric Gottenberg, Gilles Chiocchia
Current Opinion in Rheumatology|July 31, 2010
Pathogenesis of Sjögren's syndrome and therapeutic consequencesXavier Mariette, Jacques-Eric Gottenberg
The Lancet. Rheumatology|January 26, 2024
Advances in treatments for Sjögren's syndrome: the glass is half fullRenaud Felten, Jacques Eric Gottenberg
Joint Bone Spine|June 24, 2008
Rituximab: a new therapeutic alternative in rheumatoid arthritisJean Sibilia, Jacques-Eric Gottenberg, Xavier Mariette
La Revue Du Praticien|March 14, 2012
[Diagnostic criteria for Sjögren's syndrome]Coralie Varoquier, Jean Sibilia, Jacques-Eric Gottenberg
Pageof 32